Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4489-4505
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4489
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4489
Table 1 The top 10 most popular countries/regions conducting research on olaparib and pancreatic cancer
| Rank | Country | Counts | TLCS | TGCS |
| 1 | United States | 83 | 320 | 4760 |
| 2 | China | 48 | 16 | 366 |
| 3 | United Kingdom | 31 | 241 | 3748 |
| 4 | France | 19 | 140 | 1537 |
| 5 | Italy | 19 | 124 | 1040 |
| 6 | Germany | 16 | 192 | 2254 |
| 7 | Spain | 12 | 186 | 2352 |
| 8 | Australia | 9 | 75 | 1746 |
| 9 | Belgium | 9 | 130 | 1391 |
| 10 | Israel | 9 | 179 | 2120 |
Table 2 The top 20 most popular authors conducting research on olaparib and pancreatic cancer
| Rank | Author | Counts | TLCS | TGCS |
| 1 | O'Reilly EM | 11 | 135 | 1177 |
| 2 | Golan T | 9 | 132 | 979 |
| 3 | Hammel P | 8 | 130 | 956 |
| 4 | Macarulla T | 7 | 127 | 947 |
| 5 | Hochhauser D | 5 | 127 | 944 |
| 6 | Seufferlein T | 5 | 17 | 140 |
| 7 | Van Cutsem E | 5 | 127 | 944 |
| 8 | Algul H | 4 | 131 | 976 |
| 9 | Brody JR | 4 | 22 | 240 |
| 10 | Cornelissen B | 4 | 4 | 72 |
| 11 | Kleger A | 4 | 17 | 135 |
| 12 | Lawrence TS | 4 | 18 | 247 |
| 13 | Morgan MA | 4 | 18 | 247 |
| 14 | Park JO | 4 | 127 | 942 |
| 15 | Parsels LA | 4 | 18 | 247 |
| 16 | Perkhofer L | 4 | 17 | 135 |
| 17 | Arnold D | 3 | 118 | 919 |
| 18 | Balmana J | 3 | 68 | 1407 |
| 19 | Biankin AV | 3 | 5 | 49 |
| 20 | Cavalli A | 3 | 6 | 36 |
Table 3 The 15 most productive institutions regarding olaparib and pancreatic cancer research
| Rank | Institution | Country | Counts | TLCS | TGCS |
| 1 | Memorial Sloan-Kettering Cancer Center | United States | 14 | 147 | 1667 |
| 2 | AstraZeneca | United Kingdom | 13 | 208 | 2755 |
| 3 | University of Michigan | United States | 10 | 36 | 752 |
| 4 | Harvard Medical School | United States | 7 | 15 | 173 |
| 5 | University of Bologna | Italy | 7 | 6 | 92 |
| 6 | University of Pennsylvania | United States | 7 | 62 | 1254 |
| 7 | Dana-Farber Cancer Institute | United States | 6 | 21 | 633 |
| 8 | Beaujon Hospital | France | 6 | 121 | 931 |
| 9 | Tel Aviv University | Israel | 6 | 110 | 907 |
| 10 | University of Oxford | United Kingdom | 6 | 18 | 192 |
| 11 | University of Texas, MD Anderson Cancer Center | United States | 6 | 27 | 859 |
| 12 | Vall d’Hebron University Hospital | Spain | 6 | 130 | 1163 |
| 13 | Sheba Medical Center | Israel | 5 | 70 | 1220 |
| 14 | University College London | United Kingdom | 5 | 127 | 1150 |
| 15 | University of Glasgow | United Kingdom | 5 | 7 | 105 |
Table 4 The top 10 journals publishing research on olaparib and pancreatic cancer
| Rank | Journal | Counts | IF 2021 | TLCS | TGCS |
| 1 | Cancers | 13 | 6.575 | 0 | 94 |
| 2 | Clinical Cancer Research | 7 | 13.801 | 16 | 169 |
| 3 | International Journal of Molecular Sciences | 5 | 6.208 | 0 | 14 |
| 4 | Annals of Oncology | 4 | 51.769 | 43 | 566 |
| 5 | European Journal of Medicinal Chemistry | 4 | 7.088 | 8 | 139 |
| 6 | Journal of Clinical Oncology | 4 | 50.717 | 74 | 1293 |
| 7 | BMC Cancer | 3 | 4.638 | 0 | 13 |
| 8 | British Journal of Cancer | 3 | 9.075 | 6 | 99 |
| 9 | Cancer Biology & Therapy | 3 | 4.875 | 0 | 6 |
| 10 | Cancer Research | 3 | 13.312 | 11 | 75 |
Table 5 The top 10 cocited references related to olaparib and pancreatic cancer
| Rank | Ref. | Title | Citations | Journal |
| 1 | Golan et al[11], 2019 | Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic cancer | 103 | The New England Journal of Medicine |
| 2 | Kaufman et al[35], 2015 | Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation | 56 | Journal of Clinical Oncology |
| 3 | Farmer et al[36], 2005 | Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | 52 | Nature |
| 4 | Robson et al[10], 2017 | Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | 46 | The New England Journal of Medicine |
| 5 | Bryant et al[37], 2005 | Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | 44 | Nature |
| 6 | Murai et al[38], 2012 | Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors | 40 | Cancer Research |
| 7 | Waddell et al[39], 2015 | Whole genomes redefine the mutational landscape of pancreatic cancer | 39 | Nature |
| 8 | Fong et al[40], 2009 | Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | 37 | The New England Journal of Medicine |
| 9 | Moore et al[21], 2018 | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | 37 | The New England Journal of Medicine |
| 10 | Conroy et al[4], 2011 | FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer | 36 | The New England Journal of Medicine |
- Citation: Feng X, Chai YH, Jiang KX, Jiang WB, Chen WC, Pan Y. Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective. World J Gastrointest Oncol 2024; 16(11): 4489-4505
- URL: https://www.wjgnet.com/1948-5204/full/v16/i11/4489.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i11.4489